Latest News and Press Releases

Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT Q1 2022 cash position of $657.4 million Expect to file INDs this year for ex vivo hypoimmune allogeneic...

SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...

SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that five abstracts...

Plans to present data at multiple scientific conferences in 2022 Expects to file INDs for leading CAR T ex vivo program, SC291, and in vivo program, SG295, in 2022 2021 year-end cash position of...

SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...

SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that preclinical data...

License will enable Sana’s in vivo and ex vivo engineered T cell programs for B cell malignancies Technology expected to help address key relapse challenges for CD19-directed CAR T cell therapies ...

SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China and SHANGHAI, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...

SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...

Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells CD8- and CD4-targeted fusosomes generated functional...